GANX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 14, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Gain Therapeutics Appoints Jeanette Weidner as Vice President, Finance and Principal Financial Officer

Oct 28, 2026

8-K

Gain Therapeutics Announces Positive 12-Month Phase 1b Data for Rexaceract in Parkinson's Disease

Oct 1, 2026

8-K

Gain Therapeutics Announces Resignation of Principal Financial Officer and Appointment of Interim CFO

Sep 28, 2026

8-K

Gain Therapeutics Reports Q2 2026 Financial Results and FDA IND Clearance for Rexaceract

Aug 11, 2026

8-K

Gain Therapeutics Announces Operational Runway and Clinical Trial Milestones

Jul 16, 2026

8-K

Gain Therapeutics Receives FDA Authorization for Phase 2 Clinical Trial of GT-02287 in Parkinson’s Disease

Jun 29, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 17, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 26, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Weidner Jeanette (Reporting)

Oct 30, 2026

Weidner Jeanette (Reporting)

Oct 30, 2026

GOLDSTEIN DOV A MD (Reporting)

Jul 17, 2026

Nicaise Claude (Reporting)

Jul 17, 2026

Islam Khalid (Reporting)

Jul 17, 2026

Melincoff Gwen A (Reporting)

Jul 17, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Jun 4, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Jan 2, 2024

CORRESP

Form CORRESP - Correspondence

Dec 22, 2023

LETTER

Form UPLOAD - SEC-generated letter

Dec 21, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Jun 2, 2022

CORRESP

Form CORRESP - Correspondence

May 31, 2022

Gain Therapeutics, Inc. GANX · SEC Filings